Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences, Inc. (Nasdaq: COGT) generates frequent news flow as a biotechnology company developing precision therapies for genetically defined diseases. Its updates often center on the clinical and regulatory progress of bezuclastinib, a selective tyrosine kinase inhibitor designed to inhibit KIT D816V and other KIT exon 17 mutations associated with systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST).
News for COGT commonly includes clinical trial milestones from the pivotal SUMMIT, APEX and PEAK studies. SUMMIT evaluates bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM), APEX in Advanced Systemic Mastocytosis (AdvSM), and PEAK in imatinib-resistant or intolerant GIST in combination with sunitinib. Press releases have highlighted positive top-line results, detailed efficacy and safety data, and plans for New Drug Application (NDA) submissions to the U.S. Food and Drug Administration.
Investors and followers of COGT can also expect regulatory and designation announcements, such as Breakthrough Therapy Designation for bezuclastinib in specific NonAdvSM populations, as well as updates on Expanded Access Programs for eligible GIST and SM patients. Financial and corporate news appears regularly, including equity and convertible note offerings, cash runway commentary, and participation in major healthcare investor conferences like the J.P. Morgan Healthcare Conference and the Jefferies Global Healthcare Conference.
In addition, Cogent issues news on its early-stage pipeline, including a selective and potent FGFR2/3 inhibitor in Phase 1/2 and discovery programs targeting ErbB2, PI3Kα, KRAS and JAK2. For readers tracking COGT, this news page provides an organized view of trial readouts, regulatory plans, financing events and scientific presentations that shape the company’s development trajectory. Bookmark this feed to monitor Cogent’s ongoing disclosures about its precision oncology and hematology programs.
Cogent Biosciences (NASDAQ: COGT) announced positive updated data from Part 1 of its Phase 2 APEX trial evaluating bezuclastinib in advanced systemic mastocytosis (AdvSM) patients. The trial demonstrated a 52% overall response rate (ORR) per mIWG criteria, with an impressive 83% ORR for patients receiving 100 mg BID dosing.
Key highlights include a median time to response of 2.2 months, with median duration of response and progression-free survival not yet reached. The study involved 32 patients across four dose levels, showing strong efficacy with 94% of patients achieving ≥50% reduction in serum tryptase levels. The drug demonstrated a differentiated safety profile, with mainly low-grade and reversible hematological adverse events.
Top-line data from APEX Part 2 remains on track for mid-2025.
Cogent Biosciences reported significant progress in its pipeline and financial results for Q3 2024. Key highlights include:
- Completion of enrollment in the Phase 3 PEAK trial for GIST patients with 413 participants.
- Acceleration of enrollment in the SUMMIT trial for NonAdvSM and initiation of a Phase 1 trial for FGFR2 inhibitor CGT-4859.
- Strong cash position of $346 million, sufficient to fund operations into late 2026.
Financially, Cogent reported R&D expenses of $63.6 million, G&A expenses of $11.8 million, and a net loss of $70.6 million for Q3 2024. Upcoming milestones include top-line results from the PEAK, SUMMIT, and APEX trials in 2025.
Cogent Biosciences (NASDAQ: COGT) announced two presentations featuring bezuclastinib at the 66th Annual ASH Meeting in December 2024. The presentations will cover long-term follow-up data from two clinical trials: the APEX trial for Advanced Systemic Mastocytosis (AdvSM) and the SUMMIT trial for Nonadvanced Systemic Mastocytosis (NonAdvSM). Dr. Daniel DeAngelo from Dana-Farber Cancer Institute will present APEX data on December 8, while Dr. Lindsay Rein from Duke University will present SUMMIT data on December 9. The company will host an investor webcast on December 9 to review both presentations.
Cogent Biosciences announced the expansion of its pipeline with a new KRAS inhibitor program and presented preclinical data at the 2024 EORTC-NCI-AACR Symposium. The company showcased two programs: CGT6737, a pan KRAS(ON) inhibitor with selectivity over HRAS and NRAS, demonstrating 90% PD inhibition in mouse models, and CGT6297, a PI3Kα inhibitor targeting H1047R mutations affecting over 55,000 cancer patients annually. CGT6297 showed 25-fold selectivity over PI3Kα WT with superior efficacy compared to approved therapies. IND-enabling studies for CGT6297 are planned for 2025.
Cogent Biosciences (Nasdaq: COGT) has announced significant progress in its clinical trials for bezuclastinib, a potential best-in-class KIT mutant inhibitor. The Phase 3 PEAK trial for gastrointestinal stromal tumors (GIST) has completed enrollment with 413 patients, exceeding the target. The trial has also advanced past the interim futility analysis with no modifications recommended. Additionally, the SUMMIT trial for nonadvanced systemic mastocytosis (NonAdvSM) is now expected to complete enrollment in Q1 2025, earlier than initially projected. Top-line results for both trials are anticipated in the second half of 2025. The company also announced the appointment of Darara Dibabu as Vice President of Marketing.
Cogent Biosciences (Nasdaq: COGT) reported Q2 2024 financial results and business highlights. Key points include:
1. Enrollment in SUMMIT, PEAK, and APEX registration-directed trials remains on track, with topline results expected in 2025.
2. Q2 2024 ended with $390 million cash, funding operations into 2027.
3. Positive data from SUMMIT Part 1 and PEAK trials presented at EHA and ASCO.
4. New Phase 2 trial of bezuclastinib plus sunitinib in later-line GIST patients announced.
5. Q2 2024 R&D expenses increased to $54.3 million, up from $38.9 million in Q2 2023.
6. Net loss for Q2 2024 was $59.0 million, compared to $44.1 million in Q2 2023.
Cogent Biosciences announced a positive alignment with the FDA on their novel patient-reported outcome measure, MS2D2, for the SUMMIT trial targeting Nonadvanced Systemic Mastocytosis (NonAdvSM). The MS2D2 questionnaire will be used to assess symptom severity and changes in NonAdvSM patients throughout the trial, focusing on the eleven most frequent and severe symptoms. The enrollment for SUMMIT Part 2 is expected to complete by Q2 2025, with top-line results due by the end of 2025.
Additionally, Cogent aims to complete enrollment in the APEX study for Advanced Systemic Mastocytosis (AdvSM) by the end of 2024, with results expected by mid-2025. The PEAK study focusing on second-line Gastrointestinal Stromal Tumors (GIST) patients is also progressing well, with enrollment expected to finish by Q3 2024 and results anticipated by late 2025.
Cogent Biosciences announced new data from Part 1 of its SUMMIT trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM).
The data, presented at the 2024 European Hematology Association Congress, showcased significant reductions in severe symptoms and mast cell reactions for patients treated with 100 mg of bezuclastinib.
Key findings included >90% reductions in mast cell burden, >50% reductions in mast cell reactions, and improvements in skin lesions. The drug demonstrated a favorable safety profile with no serious adverse events.
Enrollment for SUMMIT Part 2 and other key studies is ongoing, with results expected between mid-2024 and year-end 2025.
Cogent Biosciences has named Cole Pinnow as Chief Commercial Officer, effective May 23, 2024. Pinnow brings 25 years of biopharmaceutical industry experience, including roles at Pfizer where he led a $5B cancer portfolio. At Cogent, Pinnow will oversee the commercial strategy for the anticipated launch of bezuclastinib, aimed at treating systemic mastocytosis (SM) and Gastrointestinal Stromal Tumors (GIST).
His appointment includes inducement equity awards of 525,000 stock options and up to 214,000 performance-based restricted stock units, encouraging long-term company growth. CEO Andrew Robbins highlighted Pinnow's expertise as important for transitioning Cogent into a fully integrated commercial organization.
Cogent Biosciences has announced positive updated lead-in data from its ongoing Phase 3 PEAK trial evaluating bezuclastinib in combination with sunitinib for treating gastrointestinal stromal tumors (GIST). The combination achieved a median progression-free survival (mPFS) of 19.4 months and a 33% objective response rate (ORR) in a subset of patients. The data will be presented at the ASCO Annual Meeting on June 1, 2024.
In addition, Cogent announced a new Phase 2 trial of bezuclastinib plus sunitinib, sponsored by the Sarcoma Alliance for Research through Collaboration (SARC), targeting later-line GIST patients. Enrollment in the PEAK trial is ahead of schedule, now expected to be completed in Q3 2024. The treatment continues to show a favorable safety profile.